Skip to main content
Netherlands News in English

Main navigation

  • Top stories
  • Health
  • Crime
  • Politics
  • Business
  • Tech
  • Culture
  • Sports
  • Weird
  • 1-1-2
Image
Logo of AstraZeneca, British-Swedish multinational pharmaceutical and biotechnology company.
Logo of Astra Zeneca, British-Swedish multinational pharmaceutical and biotechnology company. - Credit: sirajstock / DepositPhotos - License: DepositPhotos
Health
Covid-19 vaccination
AstraZeneca
general practitioners
RIVM
Monday, 26 April 2021 - 14:41

Share this article:

GP's angry RIVM vaccine leader slammed AstraZeneca

A number of general physicians expressed their dissatisfaction over an interview in which RIVM Covid-19 vaccination program director Jaap van Delden said that millions of doses of the AstraZeneca Covid-19 vaccine destined for the Netherlands will likely be given away to other countries. Van Delden said that any of the AstraZeneca vaccine doses which arrive after mid-May would not be needed, as there will be plenty of alternatives available.

GPs argued that the statement was poorly timed and was threatening to endanger already damaged turnout some places in the country were recording. The association representing general practitioners in the Netherlands, LHV, argued that, despite recent concerns over very rare side effects related to blood clots, AstraZeneca jabs still remained essential in the ongoing vaccination process.

“As far as we are concerned, it is clear: if the choice is between AstraZeneca now or possibly a different vaccine at a later time, then the choice must absolutely be AstraZeneca now. The best vaccine is always the fastest available vaccine.”, they stated.

According to them, Van Delden crossed off AstraZeneca too early, given that many GPs are now trying to vaccinate as many 60 to 65-year-olds as possible. "This doesn't help at all," one GP said on Twitter.

Following the unrest over Van Delden’s statement, the RIVM explained in a tweet posted on Saturday that AstraZeneca is “a good vaccine that offers protection against the effects of Covid-19”, and stated that the drug is certainly still needed for the vaccination of 1 million people via the general practitioner, both for the first and in the long term the second shot.

The Netherlands has ordered 11.7 million doses of AstraZeneca and an estimated 1.5 million of these have already been administered. The largest bulk is scheduled to be delivered after mid-May. On April 8, the Netherlands officially stopped using the AstraZeneca job for people younger than 60.

More like this

Image
Doctor
New Dutch whooping cough cases still high, possible decline among young children
Image
Vaccination
Covid booster for risk groups starting from Oct. 2; hospitalizations on the rise
Image
A positive result on a rapid coronavirus test. November 6, 2021
New coronavirus subvariant on the rise, RIVM says increase in infections not alarming
Image
Meningococcal Vaccine Vial
Dutch health council rejects inclusion of meningococcal B vaccine in national programme
Make NL Times your top Google source

Follow us:

Latest stories

  • 10,000 residents enroll in Utrecht’s discount transit program for low-income residents
  • ING joins other banks in tightening interest-only mortgage rules in Netherlands
  • Group files complaint over app FLO collecting sexual activity, pregnancy intentions info
  • Dutch lawmakers urge regulator to reject higher grid fees during peak hours
  • Experts dispute whether teen killed in 2020 crash was moved to ditch by a third party

Top stories

  • Heat strokes at marathons: Runners sick in Amersfoort, Utrecht, Houten; two reanimated
  • Heat emergency declared at Groningen Marathon after several runners fall ill
  • Body found in residential garden after passenger jumps from hot air balloon over Zundert
  • Unusually early heat in Netherlands gives way to cooler start of June
  • Police seek "older man in blue shirt" after fatal rail accident near Twello

© 2012-2026, NL Times, All rights reserved.

Footer menu

  • Change Privacy Settings
  • Privacy Policy
  • Contact
  • Partner Content